Moderna's Flu Vaccine Faces FDA Setback: Refusal-to-File Letter Received

SEC 8-K Filing Notice

Company: Moderna, Inc. (MRNA) Filing Date: 2026-02-11 Accession Number: 0001682852-26-000012

Items Filed

Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Summary

Moderna, Inc. announced in an 8-K filing that the FDA issued a Refusal-to-File (RTF) letter for its Biologics License Application (BLA) for mRNA-1010, its investigational seasonal influenza vaccine. The FDA's Center for Biologics Evaluation and Research (CBER) will not initiate a review of the application. This decision represents a significant setback for Moderna's efforts to expand its mRNA technology beyond COVID-19 vaccines and into the seasonal influenza market.

Key Takeaways

FDA issued a Refusal-to-File (RTF) letter for Moderna's mRNA-1010 influenza vaccine BLA.
The FDA's CBER will not initiate a review of the BLA.
The announcement was made via an 8-K filing on February 10, 2026, following the FDA's notification on February 3, 2026.
The press release regarding the RTF letter is included as Exhibit 99.1 in the filing.

Analysis

The FDA's RTF letter is a negative signal for Moderna's influenza vaccine program. It suggests that the initial BLA submission was incomplete or deficient in some way, potentially related to clinical data, manufacturing processes, or other regulatory requirements. This delay will likely push back the potential launch of mRNA-1010 and could impact investor confidence in Moderna's ability to successfully develop and commercialize mRNA vaccines for indications beyond COVID-19. Competitors in the influenza vaccine market may see this as an opportunity to further solidify their positions. Moderna will need to address the FDA's concerns and resubmit the BLA, which could involve additional clinical trials or manufacturing adjustments, adding to development costs and timelines.

This post was automatically generated from an SEC 8-K filing.